Merck
Executive Summary
Chairman Roy Vagelos receives $1 mil. in salary in 1993, 10% less than 1992 per his April 1 recommendation to board, Merck proxy statement says. Vagelos received an annual bonus of $1.2 mil., 14% less than in 1992. Merck's long term incentive program, however, paid Vagelos $1.3 mil. The LTIP pays out every other year based on performance for the preceding five years. Vagelos received no stock options during 1993; in 1992 he received a "special one-time grant" of 500,000 shares in lieu of future grants and base salary increases. The award was made in recognition that "he would reach the company's mandatory retirement age in 1994"
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth